Can Recces New Army Partnership Change the Future of Burn Wound Treatment?

Source: Kapitales Research

Highlights:

• Recce Pharmaceuticals Limited (ASX: RCE) shares rose 4.46% to $0.585 at the time of writing after signing its second CRADA with the United States Army, strengthening investor confidence.
• The new partnership with the United States Army Institute of Surgical Research (USAISR) will test RECCE® 327 Gel (R327G) on battlefield-style burn injuries, targeting dangerous bacteria like MRSA and Pseudomonas aeruginosa.
• The study highlights R327G’s potential as a next-generation hydrogel wound dressing for both military and civilian healthcare, offering a possible breakthrough in fighting antibiotic-resistant infections.

Strategic move boosts confidence in next-gen anti-infectives

Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q) traded at $0.585, up 4.46% at the time of writing, after announcing a major new collaboration with the United States Army. The company has entered into its second Cooperative Research and Development Agreement (CRADA), this time with the United States Army Institute of Surgical Research (USAISR), a global leader in combat casualty and burn care research.

Testing RECCE® 327 Gel on battlefield-style injuries

Under the new agreement, USAISR will evaluate RECCE® 327 Gel (R327G) using its highly regarded Walker-Mason rat model, which is designed to replicate real-world battlefield burn injuries. The trial aims to determine if R327G can meaningfully cut down bacterial presence in infected burn injuries. The research will specifically target two of the most dangerous pathogens found in burn patients: Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Each pathogen is known for causing severe illness and showing reduced response to standard antibiotic therapies.

Why This Breakthrough Could Impact Both Soldiers and Civilians

Burn-related infections are still one of the main reasons for patient deaths, with drug resistance playing a key role. Recce’s R327G is being developed as a broad-spectrum synthetic anti-infective hydrogel, designed to rapidly kill bacteria without contributing to resistance. This makes the product highly attractive for military field kits, where fast, reliable infection control is critical. At the same time, the gel could have wider applications in hospital burn units, trauma care, and post-surgical treatment.

Growing U.S. government interest

The new agreement expands on Recce’s earlier partnership with the U.S. Army Medical Research Institute of Infectious Diseases, underlining rising U.S. government interest in the company’s innovations. Management believes the ability to deliver R327 as a simple hydrogel dressing gives it a unique edge over traditional antibiotics. With global concern rising over drug-resistant infections, Recce’s expanding U.S. collaborations position the company as a serious contender in the race for next-generation wound care solutions — both on and off the battlefield.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au